Attitudes of patients with spondylarthritis or rheumatoid arthritis regarding biological treatment during COVID-19 pandemic: A multi-center, phone-based, cross-sectional study
Authors:
- Coskun ZateriCZCoskun Zateri
- Murat BirtaneMBMurat Birtane
- İlknur AktaşİAİlknur Aktaş
- Selda SarıkayaSSSelda Sarıkaya
- Aylin RezvaniARAylin Rezvani
- Lale AltanLALale Altan
- Nigar DursunNDNigar Dursun
- Erbil DursunEDErbil Dursun
- Nurettin TaştekinNTNurettin Taştekin
- Reyhan ÇelikerRÇReyhan Çeliker
- Şenay ÖzdolapŞÖŞenay Özdolap
- Kenan AkgünKAKenan Akgün
Open Access
- 31 December 2021
- journal article
- research article
- Published by AVES YAYINCILIK A.Ş. in Archives of Rheumatology
- Vol. 36 (4) , 473-481
Abstract
Objectives: In this study, we aimed to investigate the medical treatment attitudes of patients with spondylarthritis or rheumatoid arthritis (RA) who were using biological drugs during the novel coronavirus-2019 (COVID-19) pandemic. Patients and methods: In this multi-center, cross-sectional study, a total of 277 patients (178 males, 99 females; median age: 45 years; range, 20 to 77 years) who were using biological disease-modifying anti-rheumatic drugs (bDMARDs) for rheumatic diseases and were reached by phone between June 1st, 2020 and June 30th, 2020 were included. Demographic characteristics, working status, type of the rheumatic disease, comorbidities, smoking habits, and type of the bDMARDs were recorded. Disease activity was evaluated using the Visual Analog Scale (VAS). The patients were asked whether they continued the treatment plan, as it was before or changed and, if changed, how they changed the plan and what happened after the change. Results: Of the patients, 229 had spondylarthritis and 48 had RA. A total of 36.1% of the patients were smokers, and the most common comorbidity was hypertension (17.3%). Totally, 5.8% of the patients had a history of contact with a COVID-19 positive person. Only three (1.1%) patients were diagnosed with COVID-19 infection and none of them died. Of the patients, 64.3% continued their treatment, while 35.7% adopted various changes. Most patients made the decision about the treatment plan on their own (n=160, 57.8%), while 38.3% of them consulted their physicians and 13.9% of them consulted any health staff. The only significant parameter for changing the drug course was receiving intravenous bDMARDs (by infusion at hospital) (p=0.001). These patients had also a higher disease activity as measured by VAS, compared to the patients receiving non-infusion therapy (p=0.021). As a result of these changes, severity of the symptoms increased in 91 (32.9%) patients. Disruption of regular biological treatment and prior infusion therapy more likely worsened the complaints (pKeywords
This publication has 15 references indexed in Scilit:
- What is the true incidence of COVID-19 in patients with rheumatic diseases?Annals of the Rheumatic Diseases, 2021
- Online management of rheumatoid arthritis during COVID-19 pandemicAnnals of the Rheumatic Diseases, 2021
- Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanerceptAnnals of the Rheumatic Diseases, 2020
- Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemicClinical Medicine, 2020
- Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapyJournal of Autoimmunity, 2020
- Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapiesAnnals of the Rheumatic Diseases, 2020
- Virtually Perfect? Telemedicine for Covid-19New England Journal of Medicine, 2020
- American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID‐19 Pandemic: Version 1Arthritis & Rheumatology, 2020
- Experiences of Patients With Rheumatic Diseases in the United States During Early Days of the COVID‐19 PandemicACR Open Rheumatology, 2020
- Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderlyRheumatology, 2010